New 'Trojan Horse' Antibody Strategy Shows Promise Against All Ebola Viruses

In our new paper in Science, we describe a new therapeutic strategy to target a hidden Achilles’ heel shared by all known types of Ebola virus. This strategy relies on our development of unique bispecific antibodies that like the mythical "Trojan horse," trick Ebola into carrying the means of its own destruction into host cells. See the press release here

Fatal Attachment: Watch the Ebola virus fusion machine in action inside a human cell

Like a Trojan horse, Ebola virus sneaks into a human cell by hiding out inside lysosomes. In order to escape from the lysosome, the virus must then fuse its membrane with the membrane of the lysosome. Live imaging captures this moment of fusion in brilliant color. Images by Chandran Lab postdoctoral fellow, Dr. Jennifer Spence.

Understanding the Ebola virus

The Ebola epidemic in west Africa has highlighted the threat of emerging infectious diseases to public health. In this Nature.com webcast (registration required), Kartik outlines the importance of basic molecular research to understand how Ebola enters human cells, and why such research has been key to developing drugs and vaccines. Dr. Simon Hay (University of Oxford) also explains how mapping and modeling can help identify where are the places where Ebola and other emerging diseases risk jumping from animals to people. Watch the video (Kartik's talk only, 21 minutes).

Seminar at The Ebola Forum, Rutgers University

Kartik spoke at this symposium organized by the working group, "Zoonosis and Society: Interdisciplinary Perspectives of Animal-to-Human Disease" at Rutgers University. Its goal was to integrate the diverse perspectives of sociologists, anthropologists, epidemiologists, ecologists, clinical researchers, and molecular virologists on the Ebola outbreak in West Africa. Watch the video of Kartik's talk (34 minutes).

Researchers Study Ebola Link to Gene in Rare Disease

WallStreetJournal-logo.jpg

The Wall Street Journal interviews Kartik and Chandran Lab collaborator Steven Walkley about the connection between the rare genetic disease Niemann-Pick Type C and Ebola virus. Our research raises the possibility that a mutated NPC1 gene offers protection against Ebola infection, just as carriers of sickle-cell disease are protected against malaria. (subscription only)

More coverage on this story at The Scientist and CBSNews.com.